Bacterial Infections
Conditions
Brief summary
In this study, the therapeutic drug monitoring of teicoplanin is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then we analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of teicoplanin in Chinese children.
Interventions
DRUGTeicoplanin-PMMA
Therapeutic drug monitoring of teicoplanin
Sponsors
Qianfoshan Hospital
Shandong Provincial Hospital
Affiliated Hospital of Qinghai University
Jinan children's hospital
Yantai Yuhuangding Hospital
Jinan Central Hospital
Liaocheng People's Hospital
Shandong Tumor Hospital
Weifang People's Hospital
Linyi People's Hospital
Jining Medical University
Weihai maternal and child health care hospital
The Second Hospital of Shandong University
Shandong University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Teicoplanin was administered intravenously; * Teicoplanin was used for therapeutic purposes; * Age:≤18 years; * Clinician confirms and plans to diagnose the patient with gram-positive coccus infection; * Patients with therapeutic concentration monitoring of teicoplanin.
Exclusion criteria
* Teicoplanin was administered non-intravenously; * Teicoplanin was used for prophylactic purposes; * Patients without therapeutic concentration monitoring of teicoplanin; * Patients who die within 24 hours of the use of teicoplanin； * The blood concentrations of the patient was not approved by the quality control center.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma drug concentration | Through study completion, an average of 14 days | To detect the plasma concentrations of teicoplanin at therapeutic drug monitoring (TDM). |
Countries
China
Contacts
Primary ContactWei Zhao, Ph.D
Outcome results
None listed